Hypocretins in the control of sleep and wakefulness

Current Neurology and Neuroscience Reports

Volumn 10, Issue 3, 2010, Pages 174-179

  Bonnavion, Patricia ^a   De Lecea, Luis ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Arousal; Feeding; Hypothalamus; Narcolepsy; Optogenetics; Orexin

Indexed keywords

OREXIN; OREXIN A; OREXIN B; NEUROPEPTIDE; OREXINS; SIGNAL PEPTIDE;

ALERTNESS; AROUSAL; BEHAVIOR; BRAIN NERVE CELL; CARDIOVASCULAR SYSTEM; DIET RESTRICTION; FOOD INTAKE; HUMAN; LOCOMOTION; NARCOLEPSY; NEUROENDOCRINE SYSTEM; NEUROTRANSMISSION; NONHUMAN; PAIN; REM SLEEP; REVIEW; SLEEP; SLEEP WAKING CYCLE; SLOW WAVE SLEEP; STRESS; WAKEFULNESS; ANIMAL; BIOLOGICAL MODEL; BRAIN; METABOLISM; PHYSIOLOGY;

ANIMALS; BRAIN; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, NEUROLOGICAL; NEUROPEPTIDES; SLEEP; WAKEFULNESS;

EID: 77954948437     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-010-0101-y     Document Type: Review

References (49)

1. de Lecea L, Kilduff TS, Peyron C, et al.: The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 1998, 95:322-327.
2. Sakurai T, Amemiya A, Ishii M, et al.: Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998, 92:573-585.
3. de Lecea L, Sutcliffe JG: The hypocretins and sleep. FEBS J 2005, 272:5675-5688.
4. Peyron C, Tighe DK, van den Pol AN, et al.: Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998, 18:9996-10015.
5. Sutcliffe JG, de Lecea L: The hypocretins: excitatory neuromodulatory peptides for multiple homeostatic systems, including sleep and feeding. J Neurosci Res 2000, 62:161-168.
6. van den Pol AN: Physiological characteristics of hypocretin/ orexin neurons. In Hypocretins: Integrators of Physiological Functions. Edited by de Lecea L, Sutcliffe JG. New York: Springer; 2005:123-136.
7. Sutcliffe JG, de Lecea L: The hypocretins: setting the arousal threshold. Nat Rev Neurosci 2002, 3:339-349.
8. •• Adamantidis AR, Zhang F, Aravanis AM, et al.: Neural substrates of awakening probed with optogenetic control of hypocretin neurons. Nature 2007, 450:420-424. Adamantidis et al. applied optogenetic technology to the Hcrt system and showed that stimulation of Hcrt neurons is sufficient to increase the probability of an awakening event during slow-wave or REM sleep. This effect was blocked in Hcrt knockout mice and in the presence of an Hcrt-R1 antagonist, demonstrating that Hcrt peptides, and not other neurotransmitters, are necessary for the wake-promoting effects of Hcrt neurons.
9. Carter ME, Adamantidis A, Ohtsu H, et al.: Sleep homeostasis modulates hypocretin-mediated sleep-to-wake transitions. J Neurosci 2009, 29:10939-10949.
10. Dube MG, Kalra SP, Kalra PS: Food intake elicited by central administration of orexins/hypocretins: identification of hypothalamic sites of action. Brain Res 1999, 842:473-477.
11. Yamanaka A, Beuckmann CT, Willie JT, et al.: Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron 2003, 38:701-713.
12. Elias CF, Saper CB, Maratos-Flier E, et al.: Chemically defined projections linking the mediobasal hypothalamus and the lateral hypothalamic area. J Comp Neurol 1998, 402:442-459.
13. Horvath TL, Diano S, van den Pol AN: Synaptic interaction between hypocretin (orexin) and neuropeptide Y cells in the rodent and primate hypothalamus: a novel circuit implicated in metabolic and endocrine regulations. J Neurosci 1999, 19:1072-1087.
14. Adamantidis A, de Lecea L: Physiological arousal: a role for hypothalamic systems. Cell Mol Life Sci 2008, 65:1475-1488.
15. Adamantidis A, de Lecea L: Sleep and metabolism: shared circuits, new connections. Trends Endocrinol Metab 2008, 19:362-370.
16. Håkansson M, de Lecea L, Sutcliffe JG, et al.: Leptin receptor- and STAT3-immunoreactivities in hypocretin/orexin neurones of the lateral hypothalamus. J Neuroendocrinol 1999, 11:653-663.
17. Yamamoto Y, Ueta Y, Date Y, et al.: Down regulation of the prepro-orexin gene expression in genetically obese mice. Brain Res Mol Brain Res 1999, 65:14-22.
18. Yoshida Y, Fujiki N, Nakajima T, et al.: Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Eur J Neurosci 2001, 14:1075-1081.
19. Fujiki N, Yoshida Y, Ripley B, et al.: Changes in CSF hypocretin-1 (orexin A) levels in rats across 24 hours and in response to food deprivation. Neuroreport 2001, 12:993-997.
20. Wu MF, John J, Maidment N, et al.: Hypocretin release in normal and narcoleptic dogs after food and sleep deprivation, eating, and movement. Am J Physiol Regul Integr Comp Physiol 2002, 283:1079-1086.
21. Yamanaka A, Sakurai T, Katsumoto T, et al.: Chronic intracerebroventricular administration of orexin-A to rats increases food intake in daytime, but has no effect on body weight. Brain Res 1999, 849:248-252.
22. Boutrel B, Kenny PJ, Specio SE, et al.: Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. Proc Natl Acad Sci U S A 2005, 102:19168-19173.
23. Narita M, Nagumo Y, Hashimoto S, et al.: Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine. J Neurosci 2006, 26:398-405.
24. • Zheng H, Patterson LM, Berthoud HR: Orexin signaling in the ventral tegmental area is required for high-fat appetite induced by opioid stimulation of the nucleus accumbens. J Neurosci 2007,27:11075-11082. This study provides evidence that projections from the nucleus accumbens (a prominent player in the reward system) to hypothalamic Hcrt field, activation of Hcrt neurons, and downstream signaling through Hcrt-R1 in the ventral tegmental area are critically involved in the accumbens-driven stimulation of palatable food intake.
25. Lin L, Faraco J, Li R, et al.: The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999, 98:365-376.
26. Chemelli RM, Willie JT, Sinton CM, et al.: Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999, 98:437-451.
27. Peyron C, Faraco J, Rogers W, et al.: A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000, 6:991-997.
28. Thannickal TC, Moore RY, Nienhuis R, et al.: Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000, 27:469-474.
29. Jacobs BL, Azmitia EC: Structure and function of the brain serotonin system. Physiol Rev 1992, 72:165-229.
30. Berridge CW, Waterhouse BD: The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res Rev 2003, 42:33-84.
31. Lin JS: Brain structures and mechanisms involved in the control of cortical activation and wakefulness, with emphasis on the posterior hypothalamus and histaminergic neurons. Sleep Med Rev 2000, 4:471-503.
32. Dehaene S, Changeux JP: Reward-dependent learning in neuronal networks for planning and decision making. Prog Brain Res 2000, 126:217-229.
33. Rye DB, Jankovic J: Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology 2002, 58:341-346.
34. Jones BE: Basic mechanisms of sleep-wake states. In Principles and Practice of Sleep Medicine, edn 3. Edited by Kryger MH, Roth T, Dement WC. Philadelphia: Saunders; 2000:134-154.
35. Bourgin P, Huitrón-Résendiz S, Spier AD, et al.: Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons. J Neurosci 2000, 20:7760-7765.
36. Saper CB, Scammell TE, Lu J: Hypothalamic regulation of sleep and circadian rhythms. Nature 2005, 437:1257-1263.
37. Siegel JM: Brainstem mechanisms generating REM sleep. In Principles and Practice of Sleep Medicine, edn 3. Edited by Kryger MH, Roth T, Dement WC. Philadelphia: Saunders; 2000:112-133.
38. Wightman RM, Robinson DL: Transient changes in mesolimbic dopamine and their association with "reward." J Neurochem 2002, 82:721-735.
39. Borgland SL, Taha SA, Sarti F, et al.: Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine. Neuron 2006, 49:589-601.
40. Mileykovskiy BY, Kiyaschenko LI, Siegel JM: Behavioral correlates of activity in identified hypocretin/orexin neurons. Neuron 2005, 46:787-798.
41. Lee MG, Hassani OK, Jones BE: Discharge of identified orexin/ hypocretin neurons across the sleep-waking cycle. J Neurosci 2005, 25:6716-6720.
42. Zhang S, Zeitzer JM, Yoshida Y, et al.: Lesions of the suprachiasmatic nucleus eliminate the daily rhythm of hypocretin-1 release. Sleep 2004, 27:619-627.
43. Estabrooke IV, McCarthy MT, Ko E, et al.: Fos expression in orexin neurons varies with behavioral state. J Neurosci 2001, 21:1656-1662.
44. Vyazovskiy VV, Olcese U, Lazimy YM, et al.: Cortical firing and sleep homeostasis. Neuron 2009, 63:865-878.
45. Nishino S, Ripley B, Overeem S, et al.: Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 2001, 50:381-388.
46. Blouin AM, Thannickal TC, Worley PF, et al.: Narp immunostaining of human hypocretin (orexin) neurons: loss in narcolepsy. Neurology 2005, 65:1189-1192.
47. Crocker A, España RA, Papadopoulou M, et al.: Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Neurology 2005, 65:1184-1188.
48. • Johnson PL, Truitt W, Fitz SD, et al.: A key role for orexin in panic anxiety. Nat Med 2010, 16:111-115. This recent study based on translational experiments in a rat panic model and humans strongly suggests that aberrant functioning of the Hcrt system may underlie panic attacks and that blocking Hcrt-R1 signaling may be a therapeutic strategy to treat panic disorders.
49. • Brisbare-Roch C, Dingemanse J, Koberstein R, et al.: Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med 2007, 13:150-155. This study describes an Hcrt receptor antagonist that targets both Hcrt receptors, can be administered orally, readily crosses the blood-brain barrier, and reversibly blocks Hcrt function in vivo.